Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 3
2004 3
2005 6
2006 2
2007 1
2008 2
2009 1
2010 2
2011 1
2012 1
2013 1
2014 1
2015 2
2016 5
2017 1
2018 11
2019 5
2020 4
2021 4
2022 4
2023 1
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.
Ichikawa H, Yakushijin K, Kurata K, Tsuji T, Takemoto N, Joyce M, Okazoe Y, Takahashi R, Matsumoto S, Sakai R, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Ichikawa H, et al. Among authors: murayama t. Bone Marrow Transplant. 2024 Apr;59(4):518-525. doi: 10.1038/s41409-024-02215-4. Epub 2024 Jan 29. Bone Marrow Transplant. 2024. PMID: 38287083 Free PMC article.
Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.
Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, Murayama T, Yamazaki E, Sato S, Atsuta Y, Ishikawa Y, Sakaida E, Hatta Y, Matsumura I, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Hayakawa F, et al. Among authors: murayama t. Cancer Sci. 2025 Feb;116(2):453-461. doi: 10.1111/cas.16405. Epub 2024 Nov 21. Cancer Sci. 2025. PMID: 39572007 Free PMC article. Clinical Trial.
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Ichikawa H, Sakai H, Hojo W, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Watanabe M, et al. Among authors: murayama t. Vaccines (Basel). 2022 Oct 29;10(11):1830. doi: 10.3390/vaccines10111830. Vaccines (Basel). 2022. PMID: 36366338 Free PMC article.
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: murayama t. Hematol Oncol. 2022 Oct;40(4):667-677. doi: 10.1002/hon.2977. Epub 2022 Mar 2. Hematol Oncol. 2022. PMID: 35142384
Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.
Shiratori S, Sugita J, Ota S, Kasahara S, Ishikawa J, Tachibana T, Hayashi Y, Yoshimoto G, Eto T, Iwasaki H, Harada M, Matsuo K, Teshima T; Japan Study Group for Cell Therapy and Transplantation (JSCT). Shiratori S, et al. Bone Marrow Transplant. 2021 Jan;56(1):129-136. doi: 10.1038/s41409-020-0985-3. Epub 2020 Jul 5. Bone Marrow Transplant. 2021. PMID: 32624582 Clinical Trial.
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. Yasuda T, et al. Among authors: murayama t. Blood. 2022 Mar 24;139(12):1850-1862. doi: 10.1182/blood.2021011921. Blood. 2022. PMID: 34695176 Free article.
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.
Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H; Japan Clinical Oncology Group. Ohmachi K, et al. Among authors: murayama t. Blood Adv. 2021 Feb 23;5(4):984-993. doi: 10.1182/bloodadvances.2020002567. Blood Adv. 2021. PMID: 33591324 Free PMC article. Clinical Trial.
Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia.
Ichikawa H, Yakushijin K, Miyata Y, Kanehira H, Joyce M, Hirakawa Y, Matsumoto S, Nagao S, Sakai R, Kurata K, Kitao A, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Ichikawa H, et al. Among authors: murayama t. EJHaem. 2023 Jun 1;4(3):695-704. doi: 10.1002/jha2.728. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601886 Free PMC article.
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Ito M, Murayama T, Matsuoka H, Minami H. Watanabe M, et al. Among authors: murayama t. Vaccines (Basel). 2022 Jan 21;10(2):158. doi: 10.3390/vaccines10020158. Vaccines (Basel). 2022. PMID: 35214617 Free PMC article.
Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Mukae J, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y. Kako S, et al. Among authors: murayama t. Int J Hematol. 2021 Nov;114(5):608-619. doi: 10.1007/s12185-021-03198-4. Epub 2021 Jul 30. Int J Hematol. 2021. PMID: 34328634
56 results